Acute heart failure caused due to medical treatment-resistant cardiogenic shock, can now be treated by minimally invasive percutaneous auxiliary artificial heart support found a Cardiovascular Surgery Group research team at the Osaka University in Japan.
This method is anticipated as a new therapy for treating patients with acute heart failure due to medical treatment-resistant cardiogenic shock. Medical treatment-resistant cardiogenic shock is very difficult to treat, and mechanical circulatory support is necessary in many cases.
Conventional mechanical circulatory support devices, such as intra-aortic balloon pumping (IABP) and percutaneous cardiopulmonary support (PCPS), may not be able to fully improve hemodynamics and reduce load on left ventricular myocardium because of problems during circulatory support, such as blood pressure maintenance and retrograde blood flow (blood pressure must be continuously monitored, and retrograde blood flow increases afterload on the left ventricle).
A group of researchers led by Professor Sawa Yoshiki at the Graduate School of Medicine, Osaka University, treated a patient with acute heart failure due to medical treatment-resistant cardiogenic shock by using Impella, which is minimally invasive and can provide satisfactory circulatory support with blood flow support and anterograde blood flow, significantly improving the patient's hemodynamics.
This method, which provides sufficient circulatory assistance with minimum invasion, will become a new therapy for treating patients with acute heart failure due to medical treatment-resistant cardiogenic shock.
The growth in the proper use of this technique in Japan will save more patients with acute heart failure and improve treatment outcome.